Lab-on-Skin Platform for Organ Dysfunction
Early detection of organ dysfunction (e.g., sepsis) in critical care, oncology, and post-surgical patients
Pre-clinical/DevelopmentActive
Key Facts
Indication
Early detection of organ dysfunction (e.g., sepsis) in critical care, oncology, and post-surgical patients
Phase
Pre-clinical/Development
Status
Active
Company
About Xsensio
Xsensio is developing a novel wearable biosensor platform, Lab-on-Skin™, which leverages semiconductor-based technology to enable continuous, real-time monitoring of biochemical biomarkers like inflammation directly from the skin. Founded in 2014 as a spin-off from EPFL's Nanolab, the company aims to transform patient monitoring by providing actionable data for earlier intervention, moving from ICU settings to outpatient and home care. Backed by strong IP, a recent $7M Series A round, and collaborations with industry leaders like Texas Instruments, Xsensio is positioned to address significant unmet needs in proactive healthcare.
View full company profile